CVRx, Inc. announced at the Technology and Heart Failure Therapeutics (THT) conference that new real-world evidence demonstrates significant reductions in hospital visits and length of stay after ...

Chuck Moon, a congestive heart failure patient, experienced significant improvement in his quality of life after receiving a Barostim device implant. The Barostim device is a new technology that acts ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

FORT LAUDERDALE, Fla. (Ivanhoe Newswire) – The number of Americans living with congestive heart failure is on the rise. Heart failure is expected to affect more than 8 million people by 2030. For many ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CVRx, Inc. (NASDAQ: CVRX) on Thursday initiated the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS Category B IDE coverage and designed to evaluate the impact of Barostim in a ...

MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for ...

Late last week, the US Food and Drug Administration granted premarket approval to the Barostim Neo baroreflex activation therapy device (CVRx), which is used to improve symptoms in patients with heart ...

A new device called Barostim is helping heart failure patients at Christ Hospital in Cincinnati live more normal lives without major surgery, as experienced by local grandfather Eric Townsend.For ...

After years of work, Minnesota-based device firm CVRx has obtained approval from the Food and Drug Administration to sell its neurostimulation device for heart failure commercially in the United ...

Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is Supported by CMS Category B IDE Coverage MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE ...

MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative ...